Kidney Disease News and Research

RSS

The Lancet publishes Baxter's PREFLUCEL phase III trial results against seasonal influenza

Baxter International Inc. announced today results of a study published in this week's issue of The Lancet that demonstrate effectiveness and tolerability of Baxter's PREFLUCEL in protecting against seasonal influenza.

From Baxter International Inc. 15 Feb 2011

American Society of Nephrology introduces ASN Kidney News Mobile Edition

The American Society of Nephrology recently launched the first mobile edition of its news magazine, ASN Kidney News. ASN Kidney News highlights emerging trends in kidney health and disease.

15 Feb 2011

Harmful effects of energy drinks on children

A new study published in the journal Pediatrics on Monday examined the risks of consumption of high-caffeine energy drinks on children and young adults. The study notes that these drinks are linked to an array of serious events like heart palpitations, high blood pressure and even cardiac arrest and death. The risk rises if young adults consuming the drink suffer from chronic diseases or take other medications.

14 Feb 2011

New research: LED products actually contain hazardous substances

Those light-emitting diodes marketed as safe, environmentally preferable alternatives to traditional lightbulbs actually contain lead, arsenic and a dozen other potentially hazardous substances, according to newly published research.

13 Feb 2011

Daily diet soda raises stroke risk by 61%: Study

A new study suggests that regular intake of diet soda may be boosting the risk of stroke. Stroke is the third leading killer following heart disease and cancer, in the United States. More than 137,000 people a year die from stroke, according to the American Stroke Association.

13 Feb 2011

AHRQ: $25.3 billion spent for kidney disease treatment every year

Overall, an average of 3.7 million adults in the United States were treated for kidney disease each year between 2003 and 2007, according to the latest News and Numbers from the Agency for Healthcare Research and Quality. Kidney disease can lead to renal failure and may be caused by diabetes, high blood pressure and heart disease.

11 Feb 2011

New tool helps doctors assess likelihood of death from stroke

Researchers at St. Michael's Hospital and the Institute for Clinical and Evaluative Sciences (ICES) in Toronto have developed a new tool that will help doctors predict the probability of death in patients after an ischemic stroke.

11 Feb 2011

Intellikine, PKD Foundation to investigate novel therapies for patients with PKD

Intellikine, a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, and the PKD Foundation today announced a collaboration to investigate novel, orally-available small molecule kinase inhibitors of the TORC1 and TORC2 complexes as a potential treatment for patients with polycystic kidney disease.

11 Feb 2011

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

CeNeRx BioPharma, Inc., a clinical-stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced FDA approval of its IND and reported the first clinical results in humans for CXB909, a novel agent that has demonstrated utility in preclinical models of neuroprotection and neurodegenerative disorders.

9 Feb 2011

Study finds low awareness about kidney risks posed by diabetes

The first time that many patients realise that diabetes can affect their kidneys is when they are referred to renal services, according to a multi-cultural study in the March issue of the Journal of Renal Care.

9 Feb 2011

AMAG receives Health Canada Notice of Non-Compliance for Feraheme NDS

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that it has received a Notice of Non-Compliance (NON) from Health Canada regarding its New Drug Submission (NDS) for Feraheme® (ferumoxytol) injection for intravenous (IV) use for the treatment of iron deficiency anemia in adult chronic kidney disease patients.

9 Feb 2011

Abacus introduces new e-blood pressure control system for hospitals

Abacus Health Solutions has developed a new e-health enabled blood pressure monitoring and feedback system to improve health outcomes for hospital specialty clinics.

8 Feb 2011

Patients with kidney tumours can benefit from nephron-sparing surgery

Patients with kidney tumours larger than four centimetres are much more likely to enjoy good long-term renal function if they undergo nephron-sparing surgery rather than radical nephrectomy, according to a study in the February issue of the urology journal BJUI.

7 Feb 2011

Amgen, Pfizer present Enbrel new trial results against psoriasis at 69th AAD meeting in New Orleans, LA

Amgen and Pfizer Inc. today announced results from a new trial that demonstrated Enbrel significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology meeting in New Orleans, La.

5 Feb 2011

National Minority Quality Forum launches novel resource to map lung cancer prevalence estimates

In recognition of World Cancer Day, the National Minority Quality Forum today launched the Lung Cancer Atlas. This novel resource enables users to map lung cancer prevalence estimates and total counts at the zip-code level for the United States as well as for individual states, federal and state legislative districts.

5 Feb 2011

DaVita enters definitive agreement to acquire DSI Renal for $690 million

DaVita, announced that it has entered into a definitive agreement to acquire DSI Renal, for approximately $690 million, subject to adjustments. The company expects to close the transaction in the second or third quarter of this year.

4 Feb 2011

Merck reports GAAP net income of $861 million for 2010

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses.

4 Feb 2011

American Society of Nephrology supports US Dietary Guidelines for Americans 2010

The American Society of Nephrology (ASN) supports the recommendations, which include advising Americans to reduce their daily salt intake. The recommendations encourage nearly half of Americans to drastically reduce their salt intake.

3 Feb 2011

Losartan improves effectiveness of nanotherapeutics against cancer

Low doses of an inexpensive, FDA-approved hypertension medication may improve the results of nanotherapeutic approaches to cancer treatment. In a report in the early edition of Proceedings of the National Academy of Sciences, Massachusetts General Hospital (MGH) investigators describe experiments showing that the generic drug losartan, by modifying the network of collagen fibers that characterizes most solid tumors, improved the effectiveness of two nanotherapeutics against several types of cancer.

3 Feb 2011

Genzyme's diagnostic products sold to Sekisui Chemical for $265 million

Genzyme Corporation today announced that it has completed the sale of its diagnostic products business to Sekisui Chemical Co., Ltd. for $265 million in cash.

1 Feb 2011